Overview

Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Compare with regular regimen, the aim of this study is to testify whether having more statin during PCI will benefit in Chinese population, and to find out optimal dose of the drug for patient after PCI.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Xijing Hospital
Treatments:
Atorvastatin
Atorvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Criteria
Inclusion Criteria:

- 18-85 years old

- Patients with clinical diagnosis of ACS

- Evidence of a personally signed and dated informed consent document

Exclusion Criteria:

- Taking or, needing to take atorvastatin over than 20mg/d or any other equivalent
statin in the next 6 months, or needing to take fibrates simultaneously according to
investigators' judgment.

- LDL-C < 1.8mmol/L in patients without statin therapy in 1 months

- Endstage congestive heart failure, or LVEF < 30%

- Active hepatic disease or hepatic dysfunction, or AST/ALT > 1.5UNL

- Myopathy or increased creatine kinase (CK>2 UNL)

- Severe renal dysfunction(Scr > 3 mg/dl or 264μmol/L)

- Allergic or experienced serious adverse reaction to HMG-CoA reductase, or ineligible
to take statin as investigator's judgment

- Severe aortic valve stenosis or severe mitral stenosis, Obstructive hypertrophic
cardiomyopathy, pericardial diseases

- Pregnancy, lactation, or child bearing potential women without any effective
contraception

- Accompanied with malignant disease or other disease, which cause life expectancy < 6
months

- Participating in other interventional clinical trails using drugs or devices

- Patients with any condition which, in the investigator's judgment, might increase the
risk to the subject for any adverse event or abnormal laboratory finding